Over the course of his career, Brent Saunders, the 44-year-old CEO of drug maker Actavis, has logged more than $100 billion worth of mergers under his belt. One particular deal has dominated headlines for months now: Actavis’s $66 billion acquisition with eye care giant Allergan. The company will go by the name Allergan, but a new name is just the beginning for the new firm. Saunders talks about how the company will approach research and development — and how Allergan’s sales representatives ensured that he’s not just the head of a top 10 pharmaceutical company; he might also be one of the top 10 best-looking.
Read more of the CEO interview, “Actavis CEO Brent Saunders Has a Vision for Growth.”
